U
GrantUnlock
Health

Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)

National Institutes of Health

Opportunity #: RFA-AI-27-002

Award Ceiling
N/A
Award Floor
N/A
Close Date
Nov 10, 2026
35 days left
Total Funding
$10.0M
Posted Date
Sep 1, 2026
Cost Sharing Required
No
Grants.gov ID
360875

Description

The purpose of this notice of funding opportunity (NOFO) is to solicit applications for an Infectious Diseases Clinical Trials Network (IDCTN). The IDCTN, comprised of the Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC), supports the evaluation of interventions for emerging and chronic infections. The CTEUs design and implement clinical trials and studies, while the NCC provides the administrative and operational framework for a collaborative, integrated network and engages with experts in the field to solicit and generate clinical trial concepts. The NCC and CTEUs will collaboratively create opportunities to advance investigators early in their careers and those new to the field.

Eligible Applicants

State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and state-controlled institutions of higher education; Federally recognized Native American tribal governments; Public housing authorities or Indian housing authorities; Native American tribal organizations other than governments; Nonprofits with 501(c)(3) status; Nonprofits without 501(c)(3) status; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Other applicants

Apply on Grants.gov

Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.

View on Grants.gov
Disclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.